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MAJOR ARTICLE
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Background. The polymicrobial nature of diabetic foot infection (DFI) and the emergence of antimicrobial resistance have
complicated DFI treatment. Current treatment guidelines for deep DFI recommend coverage of methicillin-resistant Staphylococcus
aureus (MRSA) and susceptible Enterobacteriaceae. This study aimed to describe the epidemiology of DFI and to identify predictors
for DFI associated with multidrug-resistant organisms (MDROs) and pathogens resistant to recommended treatment (PRRT).
Methods. Adult patients admitted to Detroit Medical Center from January 2012 to December 2015 with DFI and positive cultures were included. Demographics, comorbidities, microbiological history, sepsis severity, and antimicrobial use within 3 months
before DFI were obtained retrospectively. DFI-PRRT was defined as a DFI associated with a pathogen resistant to both vancomycin
and ceftriaxone. DFI-MDRO pathogens included MRSA in addition to PRRT.
Results. Six-hundred forty-eight unique patients were included, with a mean age of 58.4 ± 13.7 years. DFI-MDRO accounted for
364 (56%) of the cohort, and 194 (30%) patients had DFI-PRRT. Independent predictors for DFI-PRRT included history of PRRT in
a diabetic foot ulcer, antimicrobial exposure in the prior 90 days, peripheral vascular disease, and chronic kidney disease. Long-term
care facility residence was independently associated with DFI due to ceftriaxone-resistant Enterobacteriaceae, and recent hospitalization was an independent predictor of DFI due to vancomycin-resistant Enterococcus.
Conclusions. An unexpectedly high prevalence of DFI-PRRT pathogens was identified. History of the same pathogen in a prior
diabetic foot ulcer and recent antimicrobial exposure were independent predictors of DFI-PRRT and should be considered when
selecting empiric DFI therapy.
Keywords. diabetic foot infection; empiric therapy; multidrug-resistant organisms; PRRT.
The choice of antibiotic agents for diabetic foot infection (DFI)
is challenging considering the complex microbiology of DFI,
which is often polymicrobial [1]. In addition, patients who have
diabetic foot ulcers (DFUs) frequently have conditions that
are associated with colonization and/or infection with multidrug-resistant organisms (MDROs), including frequent health
care exposures, chronic wound care, and recurrent and prolonged antibiotic treatment courses [2].
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The microbiology of DFI has been assessed in several studies outside the United States, and geographic variation of predominant pathogens has been reported [1, 3–5]. In addition,
microbiological variation exists as a function of the acuity and
depth of DFI. Whereas acute and superficial infections tend to
be monomicrobial and the most common pathogens are Grampositive cocci, chronic and deep infections are more commonly
polymicrobial and more frequently involve Gram-negative
bacilli [6].
Current national guidelines from the Infectious Diseases
Society of America (IDSA) recommend empiric treatment of
severe and deep moderate DFI with antimicrobial agents that
have activity against Staphylococcus aureus, Streptococci spp.,
and Enterobacteriaceae, whereas empiric coverage of MDROs is
recommended only if MDROs are common in the locale where
the infection is being managed or if specific MDRO risk factors
are present.
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Although early appropriate antibiotic therapy may be associated with favorable outcomes (such as wound healing and
limb salvage) [3, 4], overuse of broad-spectrum antibiotics may
further contribute to the occurrence of DFI associated with
MDROs. As MRSA prevalence is relatively high throughout the
United States, guidelines recommend that empiric therapy typically include MRSA coverage. However, routine Pseudomonas
aeruginosa coverage is not advocated, and guideline-recommended empiric antimicrobial regimens generally target more
susceptible forms of Enterobacteriaceae. Thus, in accordance
with IDSA guidelines and based on local susceptibility patterns
of S. aureus and Enterobacteriaceae, vancomycin + ceftriaxone
is a commonly employed empiric regimen for DFI at the Detroit
Medical Center (DMC).
Data related to the overall microbiological epidemiology of
DFI in the United States and risk factors for DFI due to MDROs
are scarce. Furthermore, risk factors for specific populations
with DFI due to pathogens that are resistant to recommended
empiric therapeutic regimens, such as vancomycin + ceftriaxone, are unknown.
The primary objectives of this study were to describe the
microbiologic and clinical epidemiology of DFI in patients
who were admitted to the DMC and to identify risk factors for
MDRO pathogens (DFI-MDRO). The secondary objective was
to identify risk factors for DFI associated with pathogens resistant to vancomycin + ceftriaxone in order to identify patients
who warrant empiric therapy that provides a broader spectrum
of antimicrobial coverage.
METHODS
Study Setting and Cohort Description

Multiple nested retrospective case–control studies were performed within a large cohort to determine predictors of DFI
associated with resistant pathogens. All adult patients with
DFI who were admitted to the DMC (a health system including 4 acute care hospitals and 1 rehabilitation center) between
January 2012 and December 2015 with positive cultures from
DFI lesions were included. DFI subjects were identified based
on International Classification of Diseases, 9th revision (ICD9), codes for diabetes mellitus and either skin and soft tissue
infection (SSTI) and/or osteomyelitis (ICD-9 codes that were
used were 249, 250, 680–686, 730). In addition, admission and
discharge notes, as well as podiatry and infectious diseases consultant notes, were reviewed. Confirmation of an actual diabetic foot infection was corroborated by documented signs
and symptoms of infection (erythema, warmth, pus drainage
and/or fetid odor). Patients were excluded from the study if
(1) infection status of the ulcer could not be determined from
chart review or infection was ruled out by care providers, (2)
the SSTI was not related to the foot, (3) infection following a
fracture and/or a surgical site infection was present, (4) the
only organisms recovered from DFI were coagulase-negative
2 • OFID • Henig et al

staphylococcus and/or corynebacterium (unless recovered on
multiple occasions under sterile conditions [eg, in the operative
room and/or from bone]).
This study was approved by the institutional review boards of
Wayne State University and the Detroit Medical Center.
Definitions

The date of DFI diagnosis was defined as the day of first positive
culture for a DFI episode. An index episode was defined as the
following: among subjects who had an episode of DFI associated
with an MDRO during the study period, the index episode was
the first DFI episode associated with an MDRO (DFI-MDRO).
Among subjects who did not have a DFI associated with an
MDRO during the study period, the index episode was the first
DFI episode during the study period and was considered DFINon-MDRO. Prior and recurrent DFI episodes for all subjects
were captured throughout the study period. Thus, during the
study period, all DFI episodes for study subjects were captured.
For the purposes of this analysis, MDROs included methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococci (VRE), Enterobacteriaceae resistant to third-generation cephalosporins and/or to a carbapenem, and all antimicrobial susceptibility phenotypes of Pseudomonas aeruginosa,
Acinetobacter baumannii, and Stenotrophomonas maltophilia.
Guidelines for empiric treatment of DFI recommended
coverage of MRSA and susceptible strains of Enterobacteriaceae.
As ceftriaxone offered a significant in vitro activity advantage
over earlier-generation cephalosporins at the DMC, ceftriaxone
was considered an appropriate empiric regimen for susceptible
strains of Enterobacteriaceae [1]. Therefore, for this study, pathogens resistant to recommended empiric treatment (PRRT)
were defined as aerobic Gram-negative bacilli resistant to ceftriaxone (including resistant strains of Enterobacteriaceae and
all strains of P. aeruginosa, A. baumannii, and S. maltophilia)
and Enterococci resistant to vancomycin. MRSA was excluded
from the PRRT definition. As coverage for anaerobic organisms
is controversial and not routinely recommended in guidelines,
these organisms were not considered with regards to determining the appropriateness of therapy.
Study Variables

Data pertaining to demographics, source of admission (home,
long-term care facility [LTCF], transfer from another hospital),
hospitalization within the past 90 days, comorbidities included
in Charlson Comorbidity Index (according to ICD-9 codes and/
or physician documentation), insurance type, severity of sepsis at
time of DFI episode diagnosis (defined by the most abnormal values of systemic inflammatory response syndrome score and vital
signs within 2 days of DFI diagnosis) [7], admission unit, highest
HbA1C value within 3 months of DFI episode, diabetes-related
end-organ damage, and ankle-brachial index (ABI) values were
obtained from the medical record. The depth of involvement
of DFI was determined based on providers’ documentation,

radiology findings, and pathology findings and was classified as
superficial, deep tissue, or bone involvement [8]. Antimicrobial
treatment information in the prior 3 months was abstracted
from the medical record. Intensive care unit (ICU) admission
and mechanical ventilation and acute hemodialysis status were
captured within 7 days of the date of the DFI diagnosis. Surgical
interventions were recorded for current and prior DFI episodes,
including bedside debridement, operating room debridement,
and amputations.
Microbiology

Microbiology data for each patient included cultures obtained
from DFI lesions and were categorized according to the anatomic depth of the lesion from which the culture was obtained
and the type of specimen obtained. Specimen types were categorized as swab cultures obtained at the bedside, tissue cultures
obtained at the bedside, swab cultures obtained in the operating room, tissue cultures obtained in the operating room, and
bone cultures collected in the operating room. For a given episode, all cultures from the DFI site that were obtained within a
period of 14 days of the initial culture (and thus, within 14 days
of the index episode) were considered part of the index DFI episode. A polymicrobial episode was defined as an episode during which more than 1 pathogen was recovered. Bloodstream
infection associated with DFI was defined as growth of the same
pathogen in the blood as was recovered from the DFI lesion
within 7 days of DFI diagnosis. A prior recovery of an MDRO
in a diabetic foot ulcer was defined as a history of infection or
colonization of a DFU with 1 or more MDROs during the study
period and, for subjects enrolled during the first year of the
study, for 1 year before the subject’s index DFI episode.

model”). Backwards stepwise regression was performed to
identify independent predictors for DFI-MDRO. Variables not
selected were evaluated for confounding. If a variable impacted
the Beta coefficient value of 1 or more of the selected variables by ≥10%, it was considered a confounder and was left in
the model. Similar analysis methodology was implemented to
identify independent predictors for DFI-PRRT and for each of
PRRT pathogens individually. All P values were 2-sided.
RESULTS
Cohort

Between 2012 and 2015, 1210 subjects who had diabetes mellitus, SSTI and/or osteomyelitis, and a wound culture obtained
were identified. Five hundred sixty-two patients were excluded
for the following reasons: absence of positive cultures, SSTI
located in an area other than the foot, documentation of noninfected DFU, or isolation of coagulase-negative Staphylococci
or Corynobacterium spp. from a single nonsterile culture.
Six-hundred forty-eight unique patients were determined to
have DFI per the study definition and were included in the
study cohort (Figure 1). Overall, there were 963 DFI episodes
throughout the entire study period, 648 were categorized as

1210 Unique patients with
SSTI or Osteoyelitis
and
diabetes mellitus

562 Patients excluded:

Data Analysis

Epidemiology of the cohort and prevalence of MDROs were
calculated using means and standard deviations, and medians
with interquartile ranges (IQRs). To identify risk factors for DFI
associated with MDRO (DFI-MDRO) and for DFI associated
with PRRT (DFI-PRRT), patients who had DFI-MDRO were
compared with patients who had DFI associated with susceptible pathogens (DFI-Non-MDRO), and patients who had DFIPRRT were compared with patients who had DFI associated
with non-PRRT pathogens (DFI-Non-PRRT), using the t test or
Wilcoxon rank-sum test for continuous variables and the Fisher
exact test or chi-square test for dichotomous and categorical
variables. Risk factor analyses for individual pathogens were
performed using the same methodology as was used to determine risk factors for the PRRT group. For example, patients who
had DFI associated with P. aeruginosa (DFI-P. aeruginosa) were
compared with patients who had DFI associated with all other
pathogens, excluding P. aerugniosa (DFI-Non-P. aeruginosa).
Multivariable analysis was performed using logistic regression. Variables with a P value of <.2 in bivariable analysis
were included in the candidate multivariable model (“primary

1. Absence of positive cultures
2. Skin and soft tissue infection located
in an area other than the foot
3. Documentation of noninfected
diabetic foot uber
4. Isolation of coagulase-negative
staphylococci or corynobacterium
spp. from 1 nonsterile culture.

648 Unique patients with
diagnosed with DFI
during 2012–2015

963 DFI episodes for 648
unique patients

93 Prior DFI
episodes

648 DFI index
episodes

222 Recurrent
DFI episodes

Figure 1. Flow chart of patients who were included and excluded from the
study cohort. Abbreviations: DFI, diabetic foot infection; SSTI, skin and soft tissue
infection.
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index episodes, 93 were DFI episodes occurring before MDRODFI, and 222 were recurrent DFI episodes, following the index
episode.

ceftriaxone-resistant Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae; n = 79; 15.9% of MDRO episodes),
and VRE (n = 68; 13.7% of MDRO episodes).

Prevalence of DFI During the Entire Study Period

Demographics and Epidemiology of Index Episode and Risk Factors for
DFI-MDRO

There were 2450 organisms recovered from DFI lesions of
the 963 episodes during the study period (Table 1). Seventytwo percent (n = 691) of the episodes were polymicrobial. The
median number of pathogens recovered from DFI (IQR) was
2 (1–3). S. aureus (MSSA or MRSA) accounted for 57% of
monomicrobial cultures.
Most of the organisms (68%) grew from samples obtained
in the operating room (Supplementary Figures 1 and 2): 18%
were obtained from the bone, 28% were obtained from deep tissue, and 22% were obtained from swabs. In addition, 9% of the
organisms grew from tissue cultures that were obtained at the
bedside, and 22% grew in swab cultures that were obtained at
the bedside. The distribution of organism source was consistent
across all types of bacterial species included in the cohort.
Of 963 episodes (Table 1), DFI was associated with Grampositive cocci (GPC) in 86% of the episodes, and S. aureus was
the most common pathogen (53% of GPC; MRSA represented
58.5% of S. aureus). Gram-negative bacilli were present in 56.8%
of DFI episodes, and Enterobacteriaceae were the most common
Gram-negative pathogens (80.6%).
More than half of all episodes (n = 495; 51.4%) were associated with at least 1 MDRO. The most common MDRO
was MRSA (299 episodes; present in 60% of MDRO episodes), followed by P. aeruginosa (n = 131; 26.4% of
MDRO episodes), resistant Enterobacteriaceae (including

Table 1.

Six hundred forty-eight unique patients had index DFI episodes
during the study period. The mean age of this cohort was 58.4 ±
13.7 years, 64.3% were male, and 72.8% were African American.
The majority of patients (86.9%) were admitted from home
(Table 1). One hundred ninety-seven patients (30.4%) were
hospitalized within the 90 days before the DFI index episode.
The median Charlson Comorbidity Index score (IQR) was 5
(3–6). Additional characteristics of the cohort are presented in
Table 2. Approximately one-quarter of the patients presented
with severe sepsis or septic shock. The majority of patients who
were evaluated for depth of infection were categorized as having deep infections (n = 586; 90.4%), and 407 of these (69.5%)
involved bone.
Three-hundred sixty-four patients (56.2%) had at least 1
MDRO (DFI-MDRO). The most common MDRO was MRSA
(n = 224 patients; 61.5% of patients who had DFI-MDRO),
followed by P. aeruginosa (n = 94; 26% of DFI-MDRO), ceftriaxone-resistant Enterobacteriaceae, and VRE (Figure 2). Most
cultures were polymicrobial and were obtained in the operating
room or from bone biopsy (70%).
In bivariable analysis, patients who had DFI-MDRO were
more likely to have comorbid conditions and to be hospitalized
within 90 days before the index episode than patients who had
DFI-Non-MDRO (39% vs 19.8%; P < .001) (Table 2). Severe

Number of Organisms Recovered From DFI Lesions During the Entire Study Period and During the Index Episode

Pathogen
Gram-positivea

Pathogens During Entire Study Period
(No. Episodes = 963), No. (%)

Pathogens During Index Episode
(No. Episodes = 648), No. (%)

829 (86.0)

579 (89.4)

MRSA

299 (31.4)

224 (34.6)

MSSA

231 (23.6)

160 (24.7)

Streptococci

265 (32.0)

195 (30.1)

Enterococci (vancomycin-susceptible)

229 (23.8)

166 (25.6)

VRE
Coagulase-negative Staphylococci
Gram-negativea
Enterobacteriaceae (ceftriaxone-susceptible)
Enterobacteriaceae (ceftriaxone-resistant)
CRE

68 (7.1)

52 (8.0)

129 (13.4)

115 (17.8)

547 (56.8)

375 (57.9)

394 (40.9)

275 (42.4)

74 (7.7)

51 (7.9)

6 (0.6)

6 (0.6)

P. aeruginosa

131 (13.6)

94 (14.5)
22 (3.4)

A. baumannii

29 (3.0)

Other GNB

74 (7.9)

57 (8.8)

Anaerobes

197 (28.8)

160 (24.7)

Othersb

124 (12.9)

115 (17.7)

Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; GNB, Gram-negative bacilli; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; VRE, vancomycin-resistant Enterococci.
a

The percentages for each of the pathogens represent the proportion of pathogens of number of episodes. As some of the patients had more than 1 pathogen per episode, the sum of
the percentages is >100%.
b

Others: Corynobacterium spp., Candida spp.
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58.4 ± 13.7

160 (24.7)

Medicaid or no insurance

20 (3.1)

58 (8.95)

110 (17.7)

197 (30.4)

Other

LTCF (vs others)

Dependent status
(bedridden)

Recent hospitalization

130 (20.1)

29.7 (25.7–35.3)

Min glucose on presentation
<70 mg/dL

BMI, median (IQR), kg/m2

64 (9.9)

62 (9.6)

24 (3.7)

BSI

ICU admissionc

Mechanical ventilation

Severe sepsis and septic
shockb

154 (23.8)

249 (38.4)

Max glucose on presentation >300 mg/dL

Severity of illness

0.99 (0.68–1.19)

9 ± 2.6

ABI, median (IQR)
(n = 243)

HbA1c, mean ± SD

117 (18.1)

535 (82.6)

Neuropathy

123 (19.0)

Retinopathy

Diabetes-associated conditions

Cerebrovascular disease

62 (9.6)

PVD

61 (9.4)

CKD

Dementia

183 (28.2)

442 (68.2)

Chronic lung disease

Malignancy

210 (32.4)

158 (24.4)

CHF

Charlson Comorbidity Index,
median (IQR)

5 (3–6)

58 (8.95)

LTCF

Comorbid conditions

563 (86.9)

Home

Origin

168 (25.9)

320 (49.4)

Private

231 (35.7)

Medicare

Insurance type

Female

Entire Cohort
(n = 648)

15 (4.1)

39 (10.7)

39 (10.9)

98 (26.9)

29.4 (25.4–34.7)

80 (22.0)

134 (36.8)

0.99 (0.69–1.20)

8.8 ± 2.5

308 (84.6)

68 (18.7)

80 (22.0)

39 (10.7)

30 (8.2)

270 (74.2)

118 (32.4)

97 (26.7)

125 (34.3)

5 (3–7)

141 (38.7)

74 (21.1)

40 (11.0)

14 (3.9)

40 (11.0)

307 (84.3)

86 (23.6)

190 (52.2)

88 (24.2)

135 (37.1)

59.2 ± 13.8

DFI-MDRO
(n = 364)

9 (3.2)

21 (7.4)

25 (8.8)

56 (19.7)

30.2 (26.0–35.8)

50 (17.6)

115 (40.5)

0.99 (0.67–1.17)

9.4 ± 2.8

227 (79.9)

49 (17.3)

43 (15.1)

23 (8.1)

31 (10.9)

172 (60.6)

65 (22.9)

61 (21.5)

85 (29.9)

4 (3–6)

56 (19.7)

36 (13.2)

18 (6.3)

6 (2.4)

18 (6.3)

256 (90.1)

77 (26.2)

130 (45.8)

80 (28.3)

96 (33.8)

57.4 ± 13.6

DFI-Non-MDRO
(n = 293)

.68

.17

.43

.03

.15

.20

.37

.38

.01

.14

.68

.03

.28

.29

<.001

.008

.15

.24

<.001

<.001

.01

.05

.27

.26

.41

.09

P Value
Unadjusted

1.45 (1.00–2.09)

1.48 (1.00–2.18)

1.53 (0.99–2.38)

1.32 (0.81–2.16)

1.48 (0.74–2.95)

Adjusted ORe
(95% CI)

Cohort Description and Bivariable and Multivariable Analyses of Risk Factors for DFI Associated With MDRO and PRRT

Age, mean ± SD, y

Table 2.

13 (6.7)

23 (11.9)

18 (9.3)

51 (26.3)

29.4 (25.5–34.6)

46 (23.7)

65 (33.5)

0.99 (0.79–1.10)

8.6 ± 2.4

162 (83.5)

38 (19.6)

43 (22.2)

23 (11.9)

19 (9.8)

163 (84.0)

75 (38.7)

61 (31.4)

74 (38.1)

5 (4–7)

91 (46.9)

48 (25.8)

20 (14.0)

6 (3.1)

27 (13.9)

159 (82.8)

33 (17.0)

119 (61.3)

42 (21.7)

73 (37.6)

61.3 ± 13.7

DFI-PRRT
(n = 194)

11 (2.4)

37 (8.2)

46 (10.1)

103 (22.7)

30 (25.8–35.5)

84 (18.5)

184 (40.5)

0.99 (0.66–1.20)

9.3 ± 2.7

373 (82.2)

79 (17.4)

80 (17.6)

39 (8.6)

42 (9.3)

279 (61.5)

108 (23.8)

97 (21.4)

136 (30.0)

4 (3–6)

106 (23.4)

62 (14.2)

38 (7.5)

14 (3.1)

31 (6.8)

404 (90.0)

127 (28.0)

201 (44.3)

126 (27.8)

158 (34.8)

57.1 ± 13.6

DFI-Non-PRRT
(n = 454)

.01

.14

.78

.36

.28

.14

.09

.85

.004

.74

.51

.19

.24

.88

<.001

<.001

.007

.04

<.001

<.001

<.001

.006

.15

<.001

.53

<.001

P Value
Unadjusted

2.38 (1.51–3.77)

1.56 (1.04–2.34)

1.25 (0.77–2.02)

1.62 (0.99–2.67)

1.47 (0.76–2.85)

Adjusted ORf
(95% CI)
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16 (13.5)

37 (5.7)

50 (7.7)

117 (18.1)

41 (6.3)

Cefepime

Quinolones

Vancomycin

Clindamycin

31 (8.5)

94 (25.8)

38 (10.4)

29 (8.2)

10 (3.5)

23 (8.1)

12 (4.2)

8 (2.8)

8 (2.8)

17 (6.0)

71 (25.0)

55 (19.4)

16 (5.6)

3 (4.2)

119 (41.9)

164 (57.8)

29 (10.2)

16.3 (13.7–19.3)

64 (22.5)

DFI-Non-MDRO
(n = 293)

.009

<.001

.003

.006

.02

<.001

<.001

<.001

<.001

.05

.81

.02

.005

.35

.52

P Value
Unadjusted

1.81 (1.21–2.72)

1.26 (0.83–1.93)

2.62 (1.39–4.96)

Adjusted ORe
(95% CI)

22 (11.3)

64 (33.0)

23 (11.9)

22 (11.3)

15 (7.7)

47 (24.2)

112 (57.7)

70 (36.1)

21 (10.8)

10 (16.1)

89 (45.9)

136 (70.1)

46 (23.7)

17.7 (14.7–21.7)

47 (24.2)

DFI-PRRT
(n = 194)

19 (4.2)

53 (11.7)

27 (6.0)

15 (3.3)

18 (4.0)

36 (7.9)

127 (28.0)

110 (24.2)

20 (4.4)

9 (7.0)

187 (41.2)

271 (59.7)

49 (10.8)

16.2 (13.7–19.7)

108 (23.8)

DFI-Non-PRRT
(n = 454)

.001

<.001

.02

<.001

.05

<.001

<.001

.003

.004

.07

.30

.01

<.001

.12

.92

P Value
Unadjusted

1.96 (0.94–4.11)

1.44 (0.80–2.57)

1.31 (0.66–2.58)

1.85 (0.79–4.35)

2.16 (1.18–3.97)

2.79 (1.81–4.3)

0.99 (0.64–1.55)

2.45 (1.20–5.01)

Adjusted ORf
(95% CI)

Defined as systemic inflammatory response syndrome accompanied by end organ compromise, with or without the need for vasopressors support.

DFI-MDRO model was adjusted for prior hospitalization, LTCF residency, dependent status, and prior debridement. Odds ratios of variables that were included in the final model are presented.

DFI-PRRT model was adjusted for prior hospitalization, LTCF residency, dependent status, prior debridement, prior use of cefepime, quinolones, vancomycin, and clindamycin. Odds ratios of variables that were included in the final model are presented.

f

e

d
For the analysis of prior DFI episode, only patients who had DFIs during the first year of the study period were included (n = 190) because patients with DFI-Non-MDRO could only have prior DFI episodes if they were before the study period (per inclusion criteria, among DFI-Non-MDRO, the first episode within the study period was included, whereas for DFI-MDRO, the first DFI-MDRO episode was included).

Within 7 days of DFI diagnosis.

c

b

Highest WBC was calculated among patients who had WBC >12 000.

a

Abbreviations: ABI, ankle-brachial index; BLBLI, beta-lactam/beta-lactamase inhibitor; BMI, body mass index; BSI, bloodstream infection; CHF, congestive heart failure; CKD, chronic kidney disease; DFI, diabetic foot infection; ICU, intensive care unit;
LTCF, long-term care facility, including nursing home and long-term facilities; MAP, mean arterial pressure; MI/CAD, myocardial infarction and/or coronary artery diseases with stent inserted; PRRT, pathogens resistant to empiric recommended treatment;
TMP/SMZ, trimethoprim, sulfamethoxazole; WBC, white blood cell count.

Data are No. (%) unless otherwise presented.

33 (5.0)

25 (6.9)

66 (18.1)

83 (12.8)

BLBLI

Third-generation
cephalosporin

125 (34.3)

58 (15.9)

168 (46.2)

History of diabetic foot ulcer
associated with MDRO or
PRRT, respectively

239 (36.9)

74 (11)

Prior DFId

157 (43.1)

Prior antibiotic use (past
3 mo)

58 (9.0)

Osteomyelitis per pathology

66 (18.1)
243 (66.8)

180 (27.8)

276 (42.6)

Bone involvement

16.6 (13.9–20.7)

91 (25.0)

DFI-MDRO
(n = 364)

Prior debridement of foot
ulcer/infection

95 (18.3)

407 (62.8)

MAP <65 mmHg

155 (23.9)

16.4 (13.9–20.3)

Entire Cohort
(n = 648)

Highest WBC, median (IQR)
(n = 289)a

Continued

Acute kidney injury

Table 2.

Risk Factors for DFI Associated With Individual Pathogens Among the
PRRT Group

Percentage of each MDRO of all MDROs
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Figure 2. Index episode, diabetic foot infection– multidrug-resistant organism types. As some patients had >1 multidrug-resistant organism, the sum of
the percentages is >100%. Abbreviations: Ceftriaxone-R E, ceftriaxone-resistant
Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; VRE,
vancomycin-resistant Enterococcus spp.

sepsis and septic shock occurred more frequently upon presentation in patients with DFI-MDRO compared with those
with DFI-Non-MDRO (26.9% vs 19.7%, respectively; P = .03).
Interestingly, both groups had poor glycemic control (mean
HbA1C, 9 ± 2.6 for the entire cohort), but patients who had
DFI-MDRO had significantly lower mean HbA1C values than
patients who had DFI-Non-MDRO (8.8 vs 9.4; P = .02) (Table 2).
In multivariable analysis, independent predictors for DFIMDRO included treatment with any antibiotic within 90 days
before the index episode (odds ratio [OR], 1.81; 95% confidence
interval [CI], 1.21–2.72), history of colonization or infection of
a diabetic foot lesion with an MDRO (OR, 2.62; 95% CI, 1.39–
4.96), peripheral vascular disease (PVD; OR, 1.45; 95% CI,
1.00–2.09), and chronic kidney disease (CKD; OR, 1.48; 95%
CI, 1.00–2.18) (Table 2).
Risk Factors for DFI-PRRT

Patients with DFI-PRRT accounted for 29.9% of DFI index
episodes (n = 194). Most DFI-PRRT were due to P. aeruginosa
(Figure 2). In bivariable analysis, patients with DFI-PRRT were
older and had higher prevalence of comorbid conditions than
did patients who had DFI due to being non-PRRT (DFI-NonPRRT). In addition, patients with DFI-PRRT were more likely
to be admitted from an LTCF (14% vs 7.5%; P = .006) and to
be hospitalized in the 90 days before the index episode (46.9%
vs 23.4%; P < .001) (Table 2). Patients who had DFI-PRRT had
significantly lower mean HbA1C values than did patients who
had DFI-Non-PRRT (8.6 vs 9.3; P = .004).
In multivariable analysis, independent predictors for DFIPRRT included PVD (OR, 2.38; 95% CI, 1.51–3.77), CKD (OR,
1.56; 95% CI, 1.04–2.34), history of colonization or infection of
a diabetic foot ulcer with a PRRT (OR, 2.45; 95% CI, 1.20–5.01),
and prior use of a beta-lactam beta-lactamase inhibitor combination (OR, 2.16; 95% CI, 1.18–3.97) (Table 2).

Cohort characteristics and risk factors for each individual pathogen are presented in Supplementary Table 1. There were 94
patients with DFI associated with P. aeruginosa, 51 with ceftriaxone-resistant Enterobacteriaceae, and 52 with VRE. Of
note, patients with DFI associated with ceftriaxone-resistant
Enterobacteriaceae had the highest rate of severe sepsis and septic shock (40%).
In multivariable analysis, having had a prior diabetic foot
culture positive for the same PRRT pathogen was an independent predictor for DFI associated with P. aeruginosa (OR, 3.06;
95% CI, 1.14–8.20) and for DFI associated with VRE (OR, 7.83;
95% CI, 1.82–33.64) (Table 3).
Different prior antibiotic exposures were significantly associated with different types of Gram-negative PRRT. Prior use
of beta-lactam/beta-lactamase inhibitor (BLBLI), third- and
fourth-generation cephalosporins was an independent predictor
for DFI associated with ceftriaxone-resistant Enterobacteriaceae
(BLBLI: OR, 2.69; 95% CI, 1.18–6.15; third-generation cephalosporins: OR, 2.95; 95% CI, 1.11–7.88; cefepime: OR, 3.27; 95%
CI, 1.27–8.40), and prior use of cefepime was an independent predictor for DFI due to P. aeruginosa (OR, 2.41; 95% CI,
1.09–5.34).
With regards to prior health care exposure, residence in an
LTCF was an independent predictor only for DFI associated
with ceftriaxone-resistant Enterobacteriaceae (OR, 3.85; 95%
CI, 1.58–9.39), and recent hospitalization was an independent
predictor only for DFI associated with VRE (OR, 3.37; 95% CI,
1.66–6.84) (Table 3).
The only comorbid condition that was a PRRT risk factor was
PVD, which was significantly associated with DFI-VRE (OR,
17.51; 95% CI, 2.37–129.21) and DFI-ceftriaxone-resistant
Enterobacteriaceae (OR, 3.45; 95% CI, 1.29–9.25).
DISCUSSION

The proportion of DFI associated with pathogens that were
not covered by guideline-recommended empiric therapy regimens was higher than expected. Almost one-third of the index
episodes exhibited 1 or more pathogens resistant to the recommended empiric therapies, most commonly P. aeruginosa,
followed by ceftriaxone-resistant Enterobacteriaceae and VRE
(7.7% and 7.1%, respectively). Importantly, P. aeruginosa was
an unexpectedly common pathogen, being present in 15% of
index episodes in this study. This is notable as P. aeruginosa
is typically reported to occur in less than 10% of DFI in the
United States [9–12]. In addition, this study adds important
and striking data pertaining to the prevalence of DFI-MDRO
due to VRE and ceftriaxone-resistant Enterobacteriaceae [2, 13,
14]. Consistent with published data, MRSA, which occurred in
almost one-third of DFI cases, was the most common MDRO
[2].
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Table 3.

Independent Predictors for Individual DFI-PRRT

PAb vs Non-PA,
OR (95% CI)
(n = 94)

VREc vs Non-VRE,
OR (95% CI)
(n = 52)
3.37 (1.66–6.84)

3GCE-REd vs
Non-3GCE-RE,
OR (95% CI)
(n = 51)

Recent hospitalization

1.50 (0.91–2.46)

Residence of LTCF

1.11 (0.51–2.41)

a

3.85 (1.58–9.39)

1.00 (0.46–2.21)

Peripheral vascular disease

1.68 (0.95–2.96)

17.51 (2.37–129.21)

3.45 (1.29–9.25)

Congestive heart failure

a

a

1.31 (0.68–2.52)

Dementia

a

a

1.70 (0.68–4.27)

1.74 (0.98–3.09)

a

1.21 (0.51–2.86)

Dependent status (bedridden)
Prior debridement

a

0.97 (0.51–1.86)

a

History of diabetic foot ulcer associated
with PA

3.06 (1.14–8.20)

a

a

History of diabetic foot ulcer associated
with VRE

a

7.83 (1.82–33.64)

a

History of diabetic foot ulcer associated
with 3GCE-RE

a

a

8.95 (0.76–105.60)

Prior BLBLI use

a

a

2.69 (1.18–6.15)

Prior cephalosporin, third generation

a

a

2.95 (1.11–7.88)

2.41 (1.09–5.34)

a

3.27 (1.27–8.40)

Prior cefepime use
Prior vancomycin use

a

1.67 (0.83–3.37)

a

Abbreviations: 3GCE-RE, third-generation cephalosporin-resistant Enterobacteriaceae; BLBLI, beta-lactam/beta-lactamase inhibitor; DFI, diabetic foot infection; LTCF, long-term care facility;
NS, nonsignificant; PA, Pseudomonas aeruginosa; PRRT, pathogens resistant to empiric recommended treatment; VRE, vancomycin-resistant Enterococcus spp.
a

Variables were not included in the model.

b

Controlled for LTCF, dependent status, recent hospitalization, chronic kidney disease, peripheral vascular disease, prior quinolone use, history of PA in a diabetic foot ulcer, and prior use
of cefepime.
c

Controlled for LTCF, chronic kidney disease, prior debridement, and prior vancomycin use.

d

Controlled for dependent status, recent hospitalization, congestive heart failure, dementia, and history of 3GCE-RE in a diabetic foot ulcer.

In this study, the use of any antibiotic in the preceding
3 months was an independent predictor for DFI-MDRO, as was
prior history of an MDRO isolated in diabetic foot ulcers, PVD,
and CKD. Previous vancomycin and BLBLI approached statistical significance in the multivariable model for DFI-MDRO
(OR, 1.78; 95% CI, 0.92–3.64; OR, 1.77; 95% CI, 0.91–3.64,
respectively).
To our knowledge, this is the first study evaluating risk factors for having DFI associated with pathogens not covered by
recommended empiric therapy of DFI. Similar to risk factors
for DFI-MDRO, prior use of any antibiotic was independently
associated with DFI- PRRT (OR, 2.79; 95% CI, 1.81–4.3). Other
independent predictors for DFI-PRRT (and for DFI-MDRO)
included prior history of recovery of PRRT in a diabetic foot
ulcer, as well as PVD and CKD.
In this study, a patient who had a history of recovery of a
PRRT in a diabetic foot ulcer had a >2-fold risk for subsequently
having DFI-PRRT. This association between prior colonization
with resistant organisms and subsequent infection has been
reported with other types of infections [15, 16]. Therefore, in
addition to previous antimicrobial exposure, prior growth of a
PRRT (or MDRO) in a DFU should be considered when choosing empiric treatment for DFI.
Peripheral vascular disease and CKD were relatively common
in the study cohort. Having PVD was independently associated
with >2-fold increased risk of having DFI-PRRT. Poor vascular
8 • OFID • Henig et al

supply impairs wound healing and achieves appropriate antibiotic concentrations at the site of infection, both of which have
been associated with selection of resistant bacteria [17, 18].
However, because PVD prevalence was also very high among
patients with DFI-Non-PRRT (>60%), there was little predictive value for the presence of PVD in determining the likelihood of DFI-PRRT. In addition, having CKD increased the risk
of DFI-PRRT by more than 50%. Among patients with CKD,
it is plausible that use of lower doses of antibiotics, particularly
in the presence of poor vascular supply and tissue penetration,
might lead to subtherapeutic concentrations at the site of infection and subsequent development of antimicrobial resistance.
When individual PRRT were evaluated, a variety of different
antibiotic risk factors were identified. Consistent with previous
reports in infections other than DFI [19, 20], prior third-generation cephalosporin exposure was associated with ceftriaxone-resistant Enterobacteriaceae, and previous cefepime was
associated with P. aeruginosa. This association between previous use of cefepime and/or BLBLI and higher prevalence of
P. aeruginosa may be a marker for patients with comorbid conditions that place them at increased risk for P. aeruginosa infection. Alternatively, exposure to these antibiotics might have
inhibited the growth of competing bacteria, giving P. aeruginosa a selective advantage. Interestingly, residence in LTCF
was an independent predictor for DFI-ceftriaxone-resistant
Enterobacteriaceae but not for other MDROs. Similarly, recent

hospitalization was an independent predictor only for DFIVRE. Due to the to numerous published reports noting associations between LTCF exposure and recent hospitalization with
a variety of MDRO infections, we believe that these health care
exposures are an important risk factor to consider when choosing empiric therapy for DFI [21].
This study has limitations. As a result of its retrospective
design, data for the duration of diabetes before DFI, outpatient
management variables, and wound characteristics could not be
fully captured. However, expansive medical chart evaluation
allowed for the extraction of clinical information pertaining to
depth of infection and sepsis severity, which enabled the classification of >90% of the patients in the index cohort as having
DFI severity levels that were moderate or severe according to
IDSA criteria [1]. Also, the omission of patients from this study
who either had no culture obtained or only negative cultures
may have provided an overestimation of the incidence of DFIMDRO. The results pertaining to DFI-PRRT predictors are
most relevant to the practice at the study institution, which is
in line with guideline recommendations, but cannot be generalized to institutions that use different regimens that include
broader-spectrum empiric antibiotics. Twenty-two percent of
the cultures in the study were from bedside swabs. Bedside swab
cultures may be less specific for pathogens than other types of
cultures in the cohort. In a subgroup analysis that included DFI
episodes with deep cultures only (deep tissue and bone), the distribution of MDROs was similar to that of the original cohort,
and the independent predictors for DFI-MDRO in this cohort
were similar except for PVD, which was no longer a predictor for
DFI-MDRO (data not shown).
In conclusion, this study demonstrated that the prevalence
of MDROs and PRRT, particularly P. aeruginosa, was unexpectedly high among diabetic patients with culture-positive DFI.
History of the same MDRO in a prior diabetic foot ulcer and
prior antibiotic exposure were risk factors for most individual
types of PRRT. In addition, PVD was an independent predictor
of DFI-MDRO, DFI-PRRT, and DFI-P. aeruginosa. Clinicians
and antimicrobial stewards can utilize these variables to help
guide empiric therapeutic decisions and guidelines.
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